Wall Street’s CATL IPO Test: Will They Stand with American Security or the CCP?
The American people, Congress, and the President have spoken. Now it’s Wall Street’s turn to decide.
The American people, Congress, and the President have spoken. Now it’s Wall Street’s turn to decide.
Guardian Bikes, an American company out of Seymour, Indiana that sells direct-to-consumer, wants to ensure that it keeps manufacturing 100% of its bicycles right here in the U.S., and to do so, has received a $19 million loan from J.P. Morgan to help them.
The Department’s decision confirms what CPA has consistently warned: Chinese solar companies have been illegally circumventing U.S. trade laws through Southeast Asian shell operations, flooding the U.S. market with dumped and subsidized products directly harming the domestic solar manufacturing industry.
The Department of Defense designated CATL as a “Chinese military company” under Section 1260H of the National Defense Authorization Act on January 7. Their concern: CATL’s advanced lithium-ion batteries may one day be used to power China’s submarine fleet, replacing older battery models.
Tariffs on pharmaceutical companies isn’t just good economic policy — it benefits national security and public health.
Members of the House Ways and Means Committee gave U.S. Trade Representative Jamieson Greer a piece of their mind on Wednesday during a four-and-a-half-hour hearing—double the time he spent with the Senate Finance Committee the day before.
Is China a peer competitor in the space race? On some fronts, the answer is yes. In others, the concern is that China is moving up the value chain so quickly that its companies may soon out-price American firms across the developing world.
The Trump administration is not backing down from its America First trade agenda, and Congress has granted the executive branch the authority to use emergency powers to impose tariffs in support of that agenda, U.S. Trade Representative Jamieson Greer told the Senate Finance Committee in a hearing on Tuesday.
The United States is amid a dangerous drug shortage that endangers patients, undermines our health care system and exposes a deep vulnerability to national security. America’s overwhelming reliance on foreign manufacturers for generic drugs is at the center of it.
On April 2, President Donald Trump took bold and historic action to defend American industry with the announcement of sweeping new tariffs aimed at countering unfair foreign trade practices and reigniting U.S. manufacturing. Dubbed “Liberation Day”, this policy marks the first major step in a new era of economic revitalization—one where the United States refuses to accept the systematic dismantling of its industrial base and begins to chart a path back to true production-led prosperity.